The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from Servier. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Impact of treatment protocol deviations on outcomes in the ALL-REZ BFM 2002 study
|
Significant progress has been made in the treatment of pediatric patients with ALL; however, 15% of patients still relapse.1 While treatment protocols for patients with relapsed ALL are designed to be strictly adhered to, treatment protocol deviations during clinical trials occur regularly, and the prognostic impact of these remains unclear.1 The multicenter, randomized ALL-REZ BFM 2002 trial (NCT00114348) evaluated a risk-adapted combination of chemotherapy, allo-HSCT, and radiotherapy in patients aged <18 years with ALL in first relapse.1 A retrospective analysis assessed the characteristics of protocol deviations and their impact on outcomes in 687 patients treated in the trial. Results from this analysis were published in Leukemia by Argyriadi et al.1 |
| Key learnings |
| In a survival analysis, patients with protocol deviations (n = 94) had a lower probability of 5‐year DFS (38% vs 61%; p < 0.001) and OS (57% vs 70%; p < 0.001) compared to those who were protocol-compliant (n = 509). |
| A time-dependent multivariate analysis revealed that protocol deviation status, time of relapse, and immunologic subtype were independently associated with DFS (p ≤ 0.001). |
| Protocol deviations driven by treatment-related toxicity were associated with a lower 5-year DFS vs no deviations (36% vs 61%; p < 0.001), whereas deviations due to insufficient response did not impact 5-year DFS (49% vs 61%; p = 0.09). |
| These results suggest protocol deviations due to treatment toxicity are associated with inferior outcomes, and highlight the need for less toxic treatments and strict protocol compliance to enhance clinical outcomes in pediatric patients with relapsed ALL. |
Abbreviations: ALL, acute lymphoblastic leukemia; ALL-REZ BFM, Berlin-Frankfurt-Münster Group’s Acute Lymphoblastic Leukemia-Relapse Study; allo-HSCT, allogeneic hematopoietic stem cell transplantation; DFS, disease-free survival; OS, overall survival.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
